Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine and Sirolimus Combined With MMF or PTCy as GVHD Prophylaxis After HCT
NCT03246906Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2017
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mycophenolate mofetil, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Started Sep 2017; status: terminated.
02
Drugs
mycophenolate mofetilcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03246906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246906.